KRTX Karuna Therapeutics, Inc.

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.

$118.16  +0.40 (0.34%)
As of 06/28/2022 13:38:36 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/28/2019
Outstanding shares:  29,882,727
Average volume:  319,997
Market cap:   $3,494,187,268
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BJMLSD2
Valuation   (See tab for details)
PE ratio:   -124.97
PB ratio:   7.69
PS ratio:   94.53
Return on equity:   -37.81%
Net income %:   -464.04%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy